vs
ICU MEDICAL INC（ICUI）与INTERPARFUMS INC（IPAR）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是INTERPARFUMS INC的1.4倍（$540.7M vs $386.2M），INTERPARFUMS INC净利率更高（7.3% vs -2.9%，领先10.2%），INTERPARFUMS INC同比增速更快（6.8% vs -14.1%），INTERPARFUMS INC自由现金流更多（$145.0M vs $36.0M），过去两年INTERPARFUMS INC的营收复合增速更高（9.2% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Inter Parfums Inc是全球知名的高端香水企业，开发、生产并销售多款授权香水、身体护理及相关美妆产品，与多家顶级奢侈时尚生活方式品牌合作推出联名香氛系列，产品覆盖全球主要市场，通过百货、美妆专营店及官方电商渠道触达消费者。
ICUI vs IPAR — 直观对比
营收规模更大
ICUI
是对方的1.4倍
$386.2M
营收增速更快
IPAR
高出21.0%
-14.1%
净利率更高
IPAR
高出10.2%
-2.9%
自由现金流更多
IPAR
多$109.0M
$36.0M
两年增速更快
IPAR
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $386.2M |
| 净利润 | $-15.7M | $28.1M |
| 毛利率 | 37.5% | 61.5% |
| 营业利润率 | 1.0% | 7.1% |
| 净利率 | -2.9% | 7.3% |
| 营收同比 | -14.1% | 6.8% |
| 净利润同比 | 34.0% | 16.0% |
| 每股收益（稀释后） | $-0.63 | $0.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIIPAR
| Q4 25 | $540.7M | $386.2M | ||
| Q3 25 | $537.0M | $429.6M | ||
| Q2 25 | $548.9M | $333.9M | ||
| Q1 25 | $604.7M | $338.8M | ||
| Q4 24 | $629.8M | $361.5M | ||
| Q3 24 | $589.1M | $424.6M | ||
| Q2 24 | $596.5M | $342.2M | ||
| Q1 24 | $566.7M | $324.0M |
净利润ICUIIPAR
| Q4 25 | $-15.7M | $28.1M | ||
| Q3 25 | $-3.4M | $65.8M | ||
| Q2 25 | $35.3M | $32.0M | ||
| Q1 25 | $-15.5M | $42.5M | ||
| Q4 24 | $-23.8M | $24.2M | ||
| Q3 24 | $-33.0M | $62.3M | ||
| Q2 24 | $-21.4M | $36.8M | ||
| Q1 24 | $-39.5M | $41.0M |
毛利率ICUIIPAR
| Q4 25 | 37.5% | 61.5% | ||
| Q3 25 | 37.4% | 63.5% | ||
| Q2 25 | 37.9% | 66.2% | ||
| Q1 25 | 34.7% | 63.7% | ||
| Q4 24 | 36.1% | 64.5% | ||
| Q3 24 | 34.8% | 63.9% | ||
| Q2 24 | 34.8% | 64.5% | ||
| Q1 24 | 32.7% | 62.5% |
营业利润率ICUIIPAR
| Q4 25 | 1.0% | 7.1% | ||
| Q3 25 | 2.6% | 25.3% | ||
| Q2 25 | 1.9% | 17.7% | ||
| Q1 25 | 2.1% | 22.2% | ||
| Q4 24 | 6.0% | 10.0% | ||
| Q3 24 | 1.4% | 25.0% | ||
| Q2 24 | 1.3% | 18.9% | ||
| Q1 24 | -1.9% | 21.0% |
净利率ICUIIPAR
| Q4 25 | -2.9% | 7.3% | ||
| Q3 25 | -0.6% | 15.3% | ||
| Q2 25 | 6.4% | 9.6% | ||
| Q1 25 | -2.6% | 12.5% | ||
| Q4 24 | -3.8% | 6.7% | ||
| Q3 24 | -5.6% | 14.7% | ||
| Q2 24 | -3.6% | 10.8% | ||
| Q1 24 | -7.0% | 12.7% |
每股收益（稀释后）ICUIIPAR
| Q4 25 | $-0.63 | $0.88 | ||
| Q3 25 | $-0.14 | $2.05 | ||
| Q2 25 | $1.43 | $0.99 | ||
| Q1 25 | $-0.63 | $1.32 | ||
| Q4 24 | $-0.97 | $0.78 | ||
| Q3 24 | $-1.35 | $1.93 | ||
| Q2 24 | $-0.88 | $1.14 | ||
| Q1 24 | $-1.63 | $1.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $137.1M |
| 总债务越低越好 | — | $176.0M |
| 股东权益账面价值 | $2.1B | $880.7M |
| 总资产 | $4.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资ICUIIPAR
| Q4 25 | — | $137.1M | ||
| Q3 25 | — | $77.5M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | — | $75.3M | ||
| Q4 24 | $308.6M | $109.3M | ||
| Q3 24 | $312.5M | $78.8M | ||
| Q2 24 | $302.6M | $37.7M | ||
| Q1 24 | $251.4M | $76.1M |
总债务ICUIIPAR
| Q4 25 | — | $176.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $157.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ICUIIPAR
| Q4 25 | $2.1B | $880.7M | ||
| Q3 25 | $2.1B | $870.9M | ||
| Q2 25 | $2.1B | $839.4M | ||
| Q1 25 | $2.0B | $788.6M | ||
| Q4 24 | $2.0B | $744.9M | ||
| Q3 24 | $2.0B | $778.5M | ||
| Q2 24 | $2.0B | $717.1M | ||
| Q1 24 | $2.1B | $708.1M |
总资产ICUIIPAR
| Q4 25 | $4.1B | $1.6B | ||
| Q3 25 | $4.1B | $1.6B | ||
| Q2 25 | $4.1B | $1.6B | ||
| Q1 25 | $4.2B | $1.4B | ||
| Q4 24 | $4.2B | $1.4B | ||
| Q3 24 | $4.3B | $1.5B | ||
| Q2 24 | $4.3B | $1.4B | ||
| Q1 24 | $4.3B | $1.3B |
负债/权益比ICUIIPAR
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $146.5M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $145.0M |
| 自由现金流率自由现金流/营收 | 6.6% | 37.5% |
| 资本支出强度资本支出/营收 | 4.6% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 5.21× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $190.5M |
8季度趋势，按日历期对齐
经营现金流ICUIIPAR
| Q4 25 | $60.6M | $146.5M | ||
| Q3 25 | $56.7M | $63.9M | ||
| Q2 25 | $11.2M | $11.9M | ||
| Q1 25 | $51.3M | $-7.4M | ||
| Q4 24 | $40.2M | $138.0M | ||
| Q3 24 | $36.1M | $76.1M | ||
| Q2 24 | $82.0M | $25.5M | ||
| Q1 24 | $45.8M | $-52.0M |
自由现金流ICUIIPAR
| Q4 25 | $36.0M | $145.0M | ||
| Q3 25 | $27.6M | $57.6M | ||
| Q2 25 | $-8.5M | $-3.3M | ||
| Q1 25 | $36.7M | $-8.8M | ||
| Q4 24 | $16.1M | $136.1M | ||
| Q3 24 | $16.2M | $75.4M | ||
| Q2 24 | $62.5M | $24.4M | ||
| Q1 24 | $29.9M | $-53.0M |
自由现金流率ICUIIPAR
| Q4 25 | 6.6% | 37.5% | ||
| Q3 25 | 5.1% | 13.4% | ||
| Q2 25 | -1.5% | -1.0% | ||
| Q1 25 | 6.1% | -2.6% | ||
| Q4 24 | 2.6% | 37.7% | ||
| Q3 24 | 2.7% | 17.8% | ||
| Q2 24 | 10.5% | 7.1% | ||
| Q1 24 | 5.3% | -16.4% |
资本支出强度ICUIIPAR
| Q4 25 | 4.6% | 0.4% | ||
| Q3 25 | 5.4% | 1.5% | ||
| Q2 25 | 3.6% | 4.5% | ||
| Q1 25 | 2.4% | 0.4% | ||
| Q4 24 | 3.8% | 0.5% | ||
| Q3 24 | 3.4% | 0.2% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 2.8% | 0.3% |
现金转化率ICUIIPAR
| Q4 25 | — | 5.21× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | 0.32× | 0.37× | ||
| Q1 25 | — | -0.17× | ||
| Q4 24 | — | 5.69× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | — | -1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
